Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-21-025119
Filing Date
2021-10-12
Accepted
2021-10-12 06:15:58
Documents
55
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 817818
2 form10-k_001.jpg GRAPHIC 9913
3 ex31-1.htm EX-31.1 20152
4 ex31-2.htm EX-31.2 19203
5 ex32-1.htm EX-32.1 6875
6 ex32-2.htm EX-32.2 6702
  Complete submission text file 0001493152-21-025119.txt   3200869

Data Files

Seq Description Document Type Size
7 INLINE XBRL INSTANCE DOCUMENT nxen-20210630.xml EX-101.INS 336950
8 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nxen-20210630.xsd EX-101.SCH 36003
9 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nxen-20210630_cal.xml EX-101.CAL 36648
10 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nxen-20210630_def.xml EX-101.DEF 144257
11 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nxen-20210630_lab.xml EX-101.LAB 271856
12 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nxen-20210630_pre.xml EX-101.PRE 213098
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 000-55320 | Film No.: 211316711
SIC: 2834 Pharmaceutical Preparations